Ongoing clinical trials (https://clinicaltrials.gov) with PARPi (olaparib/niraparib/talazoparib) alone or in combination with trabectedin, temozolomide (methylating agent), irinotecan (topoisomerase I inhibitor), POLθ inhibitors, ATR inhibitors or immune checkpoint inhibitors (durvalumab/dostarlimab), amongst others, will further probe the efficacy of PARP inhibitors in advanced and refractory sarcomas. This evidence concerns the gene PARP1 and sarcoma.